$LTBR
LIGHTBRIDGE Corp

2022 Q4 Form 10-Q Financial Statement

#000147793222008047 Filed on October 31, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.113M $2.024M
YoY Change 1.98% 14.8%
% of Gross Profit
Research & Development $68.65K $172.9K
YoY Change -75.84% -60.68%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.087M $2.197M
YoY Change -8.78% -0.27%
Operating Profit -$2.125M
YoY Change 11.06%
Interest Expense $179.0K $87.94K
YoY Change 1445.51% 5573.55%
% of Operating Profit
Other Income/Expense, Net $71.34K
YoY Change -75.31%
Pretax Income -$1.908M -$2.038M
YoY Change -17.08% 6.55%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.908M -$2.038M
YoY Change -17.08% 6.55%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.17 -$183.8K
COMMON SHARES
Basic Shares Outstanding 11.58M shares 11.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.90M $31.28M
YoY Change 16.78% 93.91%
Cash & Equivalents $28.90M $31.28M
Short-Term Investments
Other Short-Term Assets $115.3K $305.9K
YoY Change 1.6% 23.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $29.02M $31.59M
YoY Change 16.71% 91.56%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $100.0K $100.0K
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $345.0K
YoY Change
Total Long-Term Assets $453.2K $107.8K
YoY Change 346.16% 6.08%
TOTAL ASSETS
Total Short-Term Assets $29.02M $31.59M
Total Long-Term Assets $453.2K $107.8K
Total Assets $29.47M $31.70M
YoY Change 18.05% 91.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $150.3K $100.0K
YoY Change 50.33% 51.52%
Accrued Expenses $200.0K $1.100M
YoY Change 100.0% 18.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $350.3K $1.190M
YoY Change 104.25% 7.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $350.3K $1.190M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $350.3K $1.190M
YoY Change 104.25% 7.45%
SHAREHOLDERS EQUITY
Retained Earnings -$144.5M -$142.6M
YoY Change 5.47% 5.86%
Common Stock $11.90K $11.54K
YoY Change 21.94% 60.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.12M $30.51M
YoY Change
Total Liabilities & Shareholders Equity $29.47M $31.70M
YoY Change 18.05% 91.04%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$1.908M -$2.038M
YoY Change -17.08% 6.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.659M -$1.036M
YoY Change 18.56% -8.51%
INVESTING ACTIVITIES
Capital Expenditures $470.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$470.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 275.2K 3.052M
YoY Change -97.47% -10.52%
NET CHANGE
Cash From Operating Activities -2.659M -1.036M
Cash From Investing Activities -470.0 0.000
Cash From Financing Activities 275.2K 3.052M
Net Change In Cash -2.385M 2.016M
YoY Change -127.68% -11.47%
FREE CASH FLOW
Cash From Operating Activities -$2.659M -$1.036M
Capital Expenditures $470.00 $0.00
Free Cash Flow -$2.660M -$1.036M
YoY Change 18.58% -8.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
LTBR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1190386 usd
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q3 us-gaap Investment Company Tax Return Of Capital Distribution
InvestmentCompanyTaxReturnOfCapitalDistribution
0 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001084554
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13500000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9759223 shares
CY2021Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
10000000000.0 usd
CY2022Q3 us-gaap Deposits
Deposits
100000.0 usd
CY2021Q2 ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
200000 usd
CY2022Q3 us-gaap Share Price
SharePrice
6.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0
CY2022Q3 ltbr Convertible Restricted Stock
ConvertibleRestrictedStock
188588 shares
CY2021Q4 ltbr Convertible Restricted Stock
ConvertibleRestrictedStock
188588 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34487
dei Entity Registrant Name
EntityRegistrantName
LIGHTBRIDGE CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1975651
dei Entity Address Address Line1
EntityAddressAddressLine1
11710 Plaza America Drive,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2000
dei Entity Address City Or Town
EntityAddressCityOrTown
Reston
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20190
dei City Area Code
CityAreaCode
571
dei Local Phone Number
LocalPhoneNumber
730-1200
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
us-gaap Investment Company Tax Return Of Capital Distribution
InvestmentCompanyTaxReturnOfCapitalDistribution
0 usd
CY2022Q3 us-gaap Assets
Assets
31698177 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1190386 usd
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11583821 shares
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
107757 usd
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9759223 shares
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172871 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2196808 usd
CY2022Q3 us-gaap Investment Company Tax Return Of Capital Distribution
InvestmentCompanyTaxReturnOfCapitalDistribution
0 usd
us-gaap Investment Company Tax Return Of Capital Distribution
InvestmentCompanyTaxReturnOfCapitalDistribution
-110000 usd
CY2021Q3 ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
288884 usd
ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
278189 usd
ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
459997 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
71335 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
288884 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
278189 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
569997 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1913806 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5700166 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5574217 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
87943 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1551 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
110465 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6183 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
0 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
0 usd
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
0 usd
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
33694 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
87943 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1551 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
110465 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
39877 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2037530 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1912255 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5589701 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5534340 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2037530 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1912255 usd
us-gaap Net Income Loss
NetIncomeLoss
-5589701 usd
us-gaap Net Income Loss
NetIncomeLoss
-5534340 usd
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
CY2021Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-135091 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-399838 usd
CY2022Q3 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
0 usd
CY2021Q3 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
59314 usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
0 usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
175211 usd
CY2022Q3 ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-2037530 usd
CY2021Q3 ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-2106660 usd
ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-5589701 usd
ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-6109389 usd
CY2022Q3 ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.18
CY2021Q3 ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.31
ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.53
ltbr Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.92
CY2022Q3 ltbr Weighted Average Number Of Common Shares Outstanding
WeightedAverageNumberOfCommonSharesOutstanding
11085657 shares
CY2021Q3 ltbr Weighted Average Number Of Common Shares Outstanding
WeightedAverageNumberOfCommonSharesOutstanding
6759662 shares
ltbr Weighted Average Number Of Common Shares Outstanding
WeightedAverageNumberOfCommonSharesOutstanding
10633664 shares
ltbr Weighted Average Number Of Common Shares Outstanding
WeightedAverageNumberOfCommonSharesOutstanding
6648803 shares
ltbr Net Incomes Loss
NetIncomesLoss
-5589701 usd
ltbr Net Incomes Loss
NetIncomesLoss
-5534340 usd
ltbr Stock Issued During Periods Value Issued For Services
StockIssuedDuringPeriodsValueIssuedForServices
30000 usd
ltbr Stock Issued During Periods Value Issued For Services
StockIssuedDuringPeriodsValueIssuedForServices
45000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
614367 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
110000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
192467 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
74751 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1033865 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
780425 usd
ltbr Increase Decrease In Accrued Legal Settlement Costs
IncreaseDecreaseInAccruedLegalSettlementCosts
0 usd
ltbr Increase Decrease In Accrued Legal Settlement Costs
IncreaseDecreaseInAccruedLegalSettlementCosts
-4200000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4103936 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8793083 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6174 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
16021 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6174 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16021 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10646998 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3411091 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10646998 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3411091 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6536888 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5398013 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24747613 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21531665 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31284501 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16133652 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
575049 usd
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
0 usd
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
39885 usd
ltbr Payment Of Accrued Liabilities With Common Stock
PaymentOfAccruedLiabilitiesWithCommonStock
15000 usd
ltbr Payment Of Accrued Liabilities With Common Stock
PaymentOfAccruedLiabilitiesWithCommonStock
69690 usd
CY2022Q1 ltbr Shares Issued To Consultant Directors For Services Amount
SharesIssuedToConsultantDirectorsForServicesAmount
15000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
264936 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2049529 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
28434397 usd
CY2022Q2 ltbr Shares Issued Registered Offerings Net Of Offering Costs Amount
SharesIssuedRegisteredOfferingsNetOfOfferingCostsAmount
2181982 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
173772 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1502642 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
29302509 usd
CY2022Q3 ltbr Shares Issued Registered Offerings Net Of Offering Costs Amount
SharesIssuedRegisteredOfferingsNetOfOfferingCostsAmount
3052153 usd
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
175659 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2037530 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
30507791 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17207557 usd
CY2021Q1 ltbr Shares Issued To Consultant Directors For Services Amount
SharesIssuedToConsultantDirectorsForServicesAmount
69690 usd
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
60068 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2011988 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15325327 usd
CY2021Q2 ltbr Conversion Of16026 Preferred Shares To1846 Shares Of Common Shares Amount
ConversionOf16026PreferredSharesTo1846SharesOfCommonSharesAmount
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
186335 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1610097 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
13916565 usd
CY2021Q3 ltbr Conversion Of20085 Preferred Shares To2382 Shares Of Common Shares Amount
ConversionOf20085PreferredSharesTo2382SharesOfCommonSharesAmount
0 usd
CY2021Q3 ltbr Shares Issued Registered Offerings Net Of Offering Costs Amount
SharesIssuedRegisteredOfferingsNetOfOfferingCostsAmount
3411091 usd
CY2021Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
15000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
54180 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1912255 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15484581 usd
CY2022Q3 us-gaap Cash
Cash
31300000 usd
CY2022Q3 ltbr Working Capital Surplus
WorkingCapitalSurplus
30400000 usd
ltbr Net Cash Used In Operating Activities
NetCashUsedInOperatingActivities
4100000 usd
us-gaap Profit Loss
ProfitLoss
-5600000 usd
CY2022Q3 ltbr Accumulated Deficit
AccumulatedDeficit
-142600000 usd
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
75000000 usd
CY2021 us-gaap Interest Income Securities Us Treasury
InterestIncomeSecuritiesUSTreasury
9000000.0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company will need additional funding by way of a combination of strategic alliances, government grants, further offerings of equity securities, or an offering of debt securities or other debt financing in order to support its future R&amp;D activities required to further enhance and complete the development of its fuel products to a proof-of-concept stage and a commercial stage thereafter.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that the Company will be able to successfully continue to conduct its operations if there is a lack of financial resources available in the future to continue its fuel development activities, and a failure to do so would have a material adverse effect on the Company’s future R&amp;D activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, contingent liabilities, potential competition with other nuclear fuel developers, including those entities developing accident tolerant fuels, changes in government regulations, support for nuclear power, changes in accounting and taxation standards, inability to achieve overall short-term and long-term R&amp;D milestones toward commercialization, future impairment charges to its assets, and global or regional catastrophic events. The Company may also be subject to various additional political, economic, and other uncertainties.</p>
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Interest Income Securities Us Treasury
InterestIncomeSecuritiesUSTreasury
20000000.0 usd
CY2021Q4 us-gaap Deposits
Deposits
15700000 usd
CY2022Q3 ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
100000 usd
ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
300000 usd
CY2021Q3 ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
300000 usd
CY2021Q1 ltbr Contributed Services Research And Development Expenses
ContributedServicesResearchAndDevelopmentExpenses
500000 usd
CY2022Q3 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
100000 usd
ltbr Leases
Leases
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASU 2016-02, <em>Leases (Topic 842)</em>, which requires recognition of most lease arrangements on the balance sheet, the Company recognizes operating lease right of use assets and liabilities at commencement date based on the present value of the future minimum lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet in accordance with the short-term lease recognition exemption. The Company applies the practical expedient to not separate lease and non-lease components for all leases that qualify. Lease expense is recognized on a straight-line basis over the lease term. The Company has only one lease for office space and the lease is for a term of 12 months without renewal options. See Note 4 for additional information. </p>
ltbr Common Stock Warrantstspolicytextblock
CommonStockWarrantstspolicytextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Common stock warrants are accounted for as a derivative in accordance with ASC 815, <em>Derivatives and Hedging,</em> if the stock warrants contain terms that could potentially require “net cash settlement” and therefore, do not meet the scope exception for treatment as a derivative. Warrant instruments that could potentially require “net cash settlement” in the absence of explicit language precluding such settlement are initially classified as derivative liabilities at their estimated fair values, regardless of the likelihood that such instruments will ever be settled in cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All outstanding warrants expired on May 16, 2022.</p>
CY2022Q2 ltbr Net Loss Attributable To Common Stockholders3
NetLossAttributableToCommonStockholders3
-2000000.0 usd
CY2021Q2 ltbr Net Loss Attributable To Common Stockholders3
NetLossAttributableToCommonStockholders3
-2100000 usd
ltbr Net Loss Attributable To Common Stockholders3
NetLossAttributableToCommonStockholders3
-5600000 usd
ltbr Net Loss Attributable To Common Stockholders3
NetLossAttributableToCommonStockholders3
-6100000 usd
CY2022Q2 ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
11085657000000 shares
CY2021Q2 ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
6759662000000 shares
ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
10633664000000 shares
ltbr Weighted Average Common Share Outstanding
WeightedAverageCommonShareOutstanding
6648803000000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2000000.0 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2100000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5600000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6100000 usd
CY2022Q2 us-gaap Dilutive Securities
DilutiveSecurities
0 usd
CY2021Q2 us-gaap Dilutive Securities
DilutiveSecurities
0 usd
us-gaap Dilutive Securities
DilutiveSecurities
0 usd
us-gaap Dilutive Securities
DilutiveSecurities
0 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-2000000.0 usd
CY2021Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-2100000 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-5600000 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-6100000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11085657000000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6759662000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10633664000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6648803000000 shares
us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0 shares
us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0 shares
CY2022Q2 ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
11085657000000 shares
CY2021Q2 ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
6759662000000 shares
ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
10633664000000 shares
ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
6648803000000 shares
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
ltbr Operating Leases Rents Expense Net
OperatingLeasesRentsExpenseNet
70000 usd
CY2021Q1 ltbr Operating Leases Rents Expense Net
OperatingLeasesRentsExpenseNet
30000 usd
ltbr Operating Leases Rents Expense Net
OperatingLeasesRentsExpenseNet
91000 usd
CY2022Q3 ltbr Warrants Outstanding
WarrantsOutstanding
0 shares
ltbr Warrants Outstanding
WarrantsOutstanding
45577 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
525903 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
568995 shares
CY2022Q3 ltbr Rsas Outstanding
RsasOutstanding
188588 shares
ltbr Rsas Outstanding
RsasOutstanding
0 shares
CY2022Q3 ltbr Rsus Outstanding
RsusOutstanding
0 shares
ltbr Rsus Outstanding
RsusOutstanding
235850 shares
CY2022Q3 ltbr Series A Convertible Preferred Stock To Common Shares
SeriesAConvertiblePreferredStockToCommonShares
0 shares
ltbr Series A Convertible Preferred Stock To Common Shares
SeriesAConvertiblePreferredStockToCommonShares
79279 shares
CY2022Q3 ltbr Series B Convertible Preferred Stock To Common Shares
SeriesBConvertiblePreferredStockToCommonShares
0 shares
ltbr Series B Convertible Preferred Stock To Common Shares
SeriesBConvertiblePreferredStockToCommonShares
286620 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
714491 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1216321 shares
CY2021Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
100000 usd
CY2022Q3 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
100000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
0 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
100000 usd
CY2022Q3 ltbr Accrued Bonuses
AccruedBonuses
1100000 usd
CY2021Q4 ltbr Accrued Bonuses
AccruedBonuses
0 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1200000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
200000 usd
ltbr Operating Lease Term
OperatingLeaseTerm
P12Y
ltbr Operating Lease Monthly Payment
OperatingLeaseMonthlyPayment
8000 usd
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
2300000000 usd
CY2022Q1 ltbr Operating Leases Rents Expense Net
OperatingLeasesRentsExpenseNet
23000 usd
CY2021Q4 ltbr Total Project Value
TotalProjectValue
50000 usd
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40000 usd
CY2021Q3 ltbr Total Project Value
TotalProjectValue
70000 usd
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30000 usd
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11539932 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
188588 shares
CY2022Q3 ltbr Stock Options Outstanding
StockOptionsOutstanding
12254423 shares
CY2022Q3 ltbr Restricted Stock Award Not Included Outstanding Shares
RestrictedStockAwardNotIncludedOutstandingShares
188588 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9759223 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
188588 shares
CY2021Q4 ltbr Stock Options Outstanding
StockOptionsOutstanding
10532101 shares
CY2021Q4 ltbr Restricted Stock Award Not Included Outstanding Shares
RestrictedStockAwardNotIncludedOutstandingShares
188588 shares
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 usd
CY2021Q4 ltbr Share Based Compensation Share Based Payment Award Options Outstanding Number
ShareBasedCompensationShareBasedPaymentAwardOptionsOutstandingNumber
538713 shares
CY2021Q4 ltbr Weighted Average Exercise Price Beginning
WeightedAverageExercisePriceBeginning
18.51
CY2021Q4 ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOptionsNonvestedWeightedAverageGrantDateFairValue
12.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
18852 shares
ltbr Weighted Average Exercise Price Stock Options Granted
WeightedAverageExercisePriceStockOptionsGranted
6.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.98
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
ltbr Weighted Average Exercise Price Stock Options Exercised
WeightedAverageExercisePriceStockOptionsExercised
0
ltbr Weighted Average Fair Value Stock Options Exercised
WeightedAverageFairValueStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
31662 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.29
ltbr Weighted Average Fair Value Stock Options Expired
WeightedAverageFairValueStockOptionsExpired
2.37
CY2022Q3 ltbr Share Based Compensation By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationByShareBasedPaymentAwardOptionsOutstandingNumber
525903 shares
CY2022Q3 ltbr Weighted Average Exercise Price End
WeightedAverageExercisePriceEnd
18.74
CY2022Q3 ltbr Share Based Compensatio By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensatioByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.23
ltbr Options Outstanding Options Exercisable
OptionsOutstandingOptionsExercisable
514513 shares
ltbr Weighted Average Exercise Price Options Exercisable
WeightedAverageExercisePriceOptionsExercisable
19.03
ltbr Weighted Average Fair Value Options Exercisable
WeightedAverageFairValueOptionsExercisable
13.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y8M1D
ltbr Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm
P4Y9M7D
CY2022Q3 ltbr Number Of Awards Stock Option Outstanding
NumberOfAwardsStockOptionOutstanding
525903 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
18.74
CY2022Q3 ltbr Number Of Awards Stock Options Vested
NumberOfAwardsStockOptionsVested
514513 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.03
ltbr Share Based Compensation Arrangement By Rs As Options Outstanding Number
ShareBasedCompensationArrangementByRSAsOptionsOutstandingNumber
377176 shares
ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue
10.69
ltbr Share Based Compensation Arrangement By Rs As Options Outstanding Number Ending
ShareBasedCompensationArrangementByRSAsOptionsOutstandingNumberEnding
377176 shares
ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Grant Date Fair Value Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueEnding
10.69
ltbr Schedule Vesting For Outstanding Rsa
ScheduleVestingForOutstandingRsa
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ending December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Scheduled vesting</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">62,862</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">62,864</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">62,862</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">188,588</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3 ltbr General And Administrative Expense Paid
GeneralAndAdministrativeExpensePaid
200000 usd
CY2021Q3 ltbr General And Administrative Expense Paid
GeneralAndAdministrativeExpensePaid
100000 usd
ltbr General And Administrative Expense Paid
GeneralAndAdministrativeExpensePaid
600000 usd
ltbr General And Administrative Expense Paid
GeneralAndAdministrativeExpensePaid
300000 usd
CY2022Q3 ltbr Total Stock Based Compensation Expense
TotalStockBasedCompensationExpense
200000 usd
CY2021Q3 ltbr Total Stock Based Compensation Expense
TotalStockBasedCompensationExpense
100000 usd
ltbr Total Stock Based Compensation Expense
TotalStockBasedCompensationExpense
600000 usd
ltbr Total Stock Based Compensation Expense
TotalStockBasedCompensationExpense
300000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13500000 shares

Files In Submission

Name View Source Status
0001477932-22-008047-index-headers.html Edgar Link pending
0001477932-22-008047-index.html Edgar Link pending
0001477932-22-008047.txt Edgar Link pending
0001477932-22-008047-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ltbr-20220930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ltbr-20220930_cal.xml Edgar Link unprocessable
ltbr-20220930_def.xml Edgar Link unprocessable
ltbr-20220930_lab.xml Edgar Link unprocessable
ltbr_10q.htm Edgar Link pending
ltbr_ex311.htm Edgar Link pending
ltbr_ex312.htm Edgar Link pending
ltbr_ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ltbr-20220930_pre.xml Edgar Link unprocessable
ltbr_10q_htm.xml Edgar Link completed